{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:48:47Z","timestamp":1792097327716,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.prrv.2026.09.005","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:05:33Z","timestamp":1790435133000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["RSV in children: an evolving story from high burden to universal prevention"],"prefix":"10.1016","author":[{"given":"Mattia","family":"Spatuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Nenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Petrarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Frassanito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Mancino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Paolo","family":"La Regina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enea","family":"Bonci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Midulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10433","key":"10.1016\/j.prrv.2026.09.005_b0005","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(24)00138-7","volume":"403","author":"Wang","year":"2024","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.prrv.2026.09.005_b0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med."},{"issue":"Suppl 2","key":"10.1016\/j.prrv.2026.09.005_b0015","first-page":"S26","article-title":"Evidence on the link between respiratory syncytial virus infection in early life and chronic obstructive lung diseases","volume":"37","author":"Baraldi","year":"2020","journal-title":"Am J Perinatol."},{"issue":"11","key":"10.1016\/j.prrv.2026.09.005_b0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(15)00255-6","article-title":"ReSViNET. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics","volume":"3","author":"Mazur","year":"2015","journal-title":"Lancet Respir Med."},{"issue":"10340","key":"10.1016\/j.prrv.2026.09.005_b0025","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Respiratory Virus Global Epidemiology Network; RESCEU investigators. Global burden of respiratory syncytial virus-associated lower respiratory tract infections in children younger than 5 years in 2019: a systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet."},{"key":"10.1016\/j.prrv.2026.09.005_b0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-immunol-051116-052206","article-title":"Protective and harmful immunity to respiratory syncytial virus infection","volume":"35","author":"Openshaw","year":"2017","journal-title":"Annu Rev Immunol."},{"issue":"3","key":"10.1016\/j.prrv.2026.09.005_b0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/jamapediatrics.2021.5177","article-title":"Trends in bronchiolitis hospitalizations, ICU use, mortality, and costs in children, 2004\u20132018","volume":"176","author":"Mahant","year":"2021","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.prrv.2026.09.005_b0040","doi-asserted-by":"crossref","unstructured":"Spatuzzo M, Corsello A, Ricc\u00f2 M, et al. Acute viral bronchiolitis before and after implementation of nirsevimab prophylaxis in Italy: a multicentre retrospective cohort study. Lancet Reg Health Eur. 2026 Aug 21;69:101823.","DOI":"10.1016\/j.lanepe.2026.101823"},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0045","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/infdis\/jiy056","article-title":"Respiratory syncytial virus seasonality: a global overview","volume":"217","author":"Obando-Pacheco","year":"2018","journal-title":"J Infect Dis."},{"issue":"10","key":"10.1016\/j.prrv.2026.09.005_b0050","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1002\/ppul.25582","article-title":"During the COVID-19 pandemic where has respiratory syncytial virus gone?","volume":"56","author":"Di Mattia","year":"2021","journal-title":"Pediatr Pulmonol."},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/aje\/kws257","article-title":"The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease","volume":"176","author":"Ohuma","year":"2012","journal-title":"Am J Epidemiol."},{"key":"10.1016\/j.prrv.2026.09.005_b0060","unstructured":"Kaler J, et al. Respiratory syncytial virus: pathogenesis, epidemiology, and prevention. 2023. PMCID: PMC10111061."},{"issue":"24","key":"10.1016\/j.prrv.2026.09.005_b0065","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1097\/CM9.0000000000003354","article-title":"Landscape of respiratory syncytial virus","volume":"137","author":"Duan","year":"2024","journal-title":"Chin Med J (Engl)."},{"issue":"4","key":"10.1016\/j.prrv.2026.09.005_b0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41579-019-0149-x","article-title":"Respiratory syncytial virus entry and how to block it","volume":"17","author":"Battles","year":"2019","journal-title":"Nat Rev Microbiol."},{"issue":"6","key":"10.1016\/j.prrv.2026.09.005_b0075","first-page":"1031","article-title":"Novel variants of respiratory syncytial virus A ON1 associated with increased clinical severity in infants with bronchiolitis","volume":"221","author":"Midulla","year":"2020","journal-title":"J Infect Dis."},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0080","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jinf.2024.106153","article-title":"Genomic evolution of human respiratory syncytial virus during recent epidemics","volume":"88","author":"Pi\u00f1ana","year":"2024","journal-title":"J Infect."},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0085","first-page":"e281","article-title":"INFORM-RSV Study Group","volume":"24","author":"Wilkins","year":"2024","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.prrv.2026.09.005_b0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coviro.2015.03.002","article-title":"Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein","volume":"11","author":"McLellan","year":"2015","journal-title":"Curr Opin Virol."},{"issue":"6161","key":"10.1016\/j.prrv.2026.09.005_b0095","first-page":"931","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science."},{"issue":"12","key":"10.1016\/j.prrv.2026.09.005_b0100","doi-asserted-by":"crossref","DOI":"10.1111\/pai.70257","article-title":"Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: mechanisms of action, failure factors, and future perspectives","volume":"36","author":"Bizot","year":"2025","journal-title":"Pediatr Allergy Immunol."},{"issue":"2","key":"10.1016\/j.prrv.2026.09.005_b0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/jcm.24.2.197-202.1986","article-title":"Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine","volume":"24","author":"Murphy","year":"1986","journal-title":"J Clin Microbiol."},{"issue":"12","key":"10.1016\/j.prrv.2026.09.005_b0110","doi-asserted-by":"crossref","first-page":"e747","DOI":"10.1016\/S1473-3099(24)00455-9","article-title":"The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access","volume":"24","author":"Terstappen","year":"2024","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"10.1016\/j.prrv.2026.09.005_b0115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0732-8893(85)90072-0","article-title":"Serological and virological investigations of young children with acute respiratory syndrome associated with respiratory syncytial virus","volume":"3","author":"Tarro","year":"1985","journal-title":"Diagn Microbiol Infect Dis."},{"issue":"21","key":"10.1016\/j.prrv.2026.09.005_b0120","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","article-title":"Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children","volume":"329","author":"Groothuis","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.prrv.2026.09.005_b0125","doi-asserted-by":"crossref","unstructured":"Palivizumab a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998 Sep;102(3):531\u2013537.","DOI":"10.1542\/peds.102.3.531"},{"issue":"1","key":"10.1016\/j.prrv.2026.09.005_b0130","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of RSV hospitalization","volume":"152","author":"Guideline Panel","year":"2023","journal-title":"Pediatrics."},{"issue":"1","key":"10.1016\/j.prrv.2026.09.005_b0135","article-title":"Palivizumab prophylaxis in infants and young children at increased risk of RSV hospitalization","volume":"152","author":"American Academy of Pediatrics","year":"2023","journal-title":"Pediatrics."},{"issue":"16","key":"10.1016\/j.prrv.2026.09.005_b0140","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for prevention of RSV in term and late-preterm infants","volume":"388","author":"Muller","year":"2023","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.prrv.2026.09.005_b0150","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of RSV hospitalizations in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1016\/j.prrv.2026.09.005_b0155","first-page":"e16","article-title":"HARMONIE Study Group","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc Health."},{"key":"10.1016\/j.prrv.2026.09.005_b0160","unstructured":"Safety and pharmacokinetics of nirsevimab in immunocompromised children aged \u226424 months: MUSIC, an open-label, phase 2 trial. Pediatrics. 2024;154(4):e2024066508."},{"issue":"2","key":"10.1016\/j.prrv.2026.09.005_b0165","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40265-022-01829-6","article-title":"Nirsevimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs."},{"key":"10.1016\/j.prrv.2026.09.005_b0170","unstructured":"U.S. Food and Drug Administration. FDA approves new drug to prevent RSV in babies and toddlers: FDA approves Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates, infants, and children up to 24 months of age [Internet]. Silver Spring (MD): FDA; 2023 Jul 17 [cited 2026 Feb 12]. Available from:https:\/\/www.fda.gov"},{"key":"10.1016\/j.prrv.2026.09.005_b0175","unstructured":"Moline HL, Toepfer AP, Tannis A, et al. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023\u20132024. JAMA Pediatr. 2025 Feb 1;179(2):179\u2013187. Erratum. In: JAMA Pediatr. 2025 Feb 1;179(2):223."},{"key":"10.1016\/j.prrv.2026.09.005_b0180","unstructured":"CDC. ACIP and AAP. Recommendations for Nirsevimab. https:\/\/publicatio ns.aap.org\/redbook\/resources\/25379\/ACIP-and-AAP-Recommendations- for-Nirsevimab."},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.15585\/mmwr.mm7309a4","article-title":"Early estimate of nirsevimab effectiveness - United States, 2023-2024 season","volume":"73","author":"Moline","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"11","key":"10.1016\/j.prrv.2026.09.005_b0190","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect Dis."},{"issue":"10","key":"10.1016\/j.prrv.2026.09.005_b0195","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S2352-4642(24)00143-3","article-title":"Effect of nirsevimab on RSV bronchiolitis hospitalisations in France, 2023\u201324","volume":"8","author":"Brault","year":"2024","journal-title":"Lancet Child Adolesc Health."},{"issue":"4","key":"10.1016\/j.prrv.2026.09.005_b0200","article-title":"Impact of nirsevimab prophylaxis in Luxembourg, 2023\/24","volume":"29","author":"Ernst","year":"2024","journal-title":"Euro Surveill."},{"issue":"8","key":"10.1016\/j.prrv.2026.09.005_b0205","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"NIRSE-GAL Study Group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"10.1016\/j.prrv.2026.09.005_b0210","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Universal nirsevimab prophylaxis in Galicia","volume":"24","author":"Ares-G\u00f3mez","year":"2024","journal-title":"Spain. Lancet Infect Dis."},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0215","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/vaccines12050549","article-title":"Safety and efficacy of nirsevimab in a universal prevention program in Valle d\u2019Aosta, Italy, 2023\u20132024","volume":"12","author":"Consolati","year":"2024","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"10.1016\/j.prrv.2026.09.005_b0220","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13052-025-01844-9","article-title":"International experiences with monoclonal antibody prophylaxis for RSV prevention","volume":"51","author":"Manti","year":"2025","journal-title":"Ital J Pediatr."},{"key":"10.1016\/j.prrv.2026.09.005_b0225","unstructured":"Pfizer Inc. European Commission approves Pfizer\u2019s Abrysvo to help protect infants through maternal immunisation against respiratory syncytial virus (RSV) [Internet]. New York (NY): Pfizer; 2023 Jul 21 [cited 2026 Feb 12]. Available from:https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/european-commission-approves-pfizers-abrysvotm-help-protect"},{"key":"10.1016\/j.prrv.2026.09.005_b0230","unstructured":"U.S. Food and Drug Administration. FDA approves first vaccine for pregnant individuals to prevent RSV in infants [Internet]. Silver Spring (MD): FDA; 2023 Aug 21 [cited 2026 Feb 12]. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants"},{"issue":"41","key":"10.1016\/j.prrv.2026.09.005_b0235","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.15585\/mmwr.mm7241e1","volume":"72","author":"Fleming-Dutra","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0240","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy (BERNI study)","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.prrv.2026.09.005_b0245","first-page":"327","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"389","author":"Kampmann","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.prrv.2026.09.005_b0250","article-title":"Real-world effectiveness of maternal RSV vaccination","author":"Halasa","year":"2024","journal-title":"JAMA Pediatr."},{"issue":"31","key":"10.1016\/j.prrv.2026.09.005_b0255","doi-asserted-by":"crossref","first-page":"484","DOI":"10.15585\/mmwr.mm7431a3","article-title":"RSV immunization coverage among infants - United States, 2023-2024","volume":"74","author":"Boundy","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.prrv.2026.09.005_b0260","unstructured":"GOV.UK. RSV maternal vaccination coverage in England: March 2025. UK Health Security Agency; 2025."},{"key":"10.1016\/j.prrv.2026.09.005_b0265","article-title":"RSV vaccine and monoclonal antibody snapshot","author":"Path","year":"2025","journal-title":"Seattle (WA): PATH"},{"key":"10.1016\/j.prrv.2026.09.005_b0270","unstructured":"U.S. Food and Drug Administration. Drug trials snapshots: Enflonsia (clesrovimab-cfor) [Internet]. Silver Spring (MD): FDA; 2025 Aug 18 [cited 2026 Feb 11]. Available from:https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-enflonsia"},{"key":"10.1016\/j.prrv.2026.09.005_b0275","unstructured":"European Commission. Commission Implementing Decision granting marketing authorisation for Enflonsia (clesrovimab). EMEA\/H\/C\/006497\/0000. 2026 Apr 15."},{"issue":"1","key":"10.1016\/j.prrv.2026.09.005_b0280","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.prrv.2026.09.005_b0285","doi-asserted-by":"crossref","unstructured":"Zar HJ, Sim\u00f5es EAF, Madhi SA et al. CLEVER (MK-1654-004) Study Group. Clesrovimab for Prevention of RSV Disease in Healthy Infants. N Engl J Med. 2025 Oct 2;393(13):1292-1303.","DOI":"10.1056\/NEJMoa2502984"},{"key":"10.1016\/j.prrv.2026.09.005_b0290","doi-asserted-by":"crossref","unstructured":"Zar HJ, Bont LJ, Manzoni P, et al. SMART (MK-1654-007) Study Group. Clesrovimab in Infants and Children at Increased Risk for Severe RSV Disease. N Engl J Med. 2025 Oct 2;393(13):1343-1345. doi: 10.1056\/NEJMc2506107. Epub 2025 Sep 17. PMID: 40961423.","DOI":"10.1056\/NEJMc2506107"},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0295","first-page":"e124","article-title":"Long-acting monoclonal antibody MK-1654 (clesrovimab) for RSV prophylaxis: phase 2b\/3 integrated data","volume":"42","author":"Shah","year":"2023","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.prrv.2026.09.005_b0300","doi-asserted-by":"crossref","unstructured":"Moulia DL, et al. Use of clesrovimab for prevention of severe respiratory syncytial virus\u2013associated lower respiratory tract infections - United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(32):[pages pending]. Available from:https:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7432a3.htm","DOI":"10.15585\/mmwr.mm7432a3"},{"issue":"32","key":"10.1016\/j.prrv.2026.09.005_b0305","doi-asserted-by":"crossref","first-page":"508","DOI":"10.15585\/mmwr.mm7432a3","article-title":"Use of clesrovimab for prevention of severe RSV LRTI in infants: ACIP recommendations-United States, 2025","volume":"74","author":"Moulia","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1016\/j.prrv.2026.09.005_b0310","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the 600 pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.prrv.2026.09.005_b0315","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01285-25","article-title":"A novel bispecific nanobody protects mice against RSV infection via intranasal administration","volume":"99","author":"Zhang","year":"2025","journal-title":"J Virol."},{"key":"10.1016\/j.prrv.2026.09.005_b0320","article-title":"Camelid nanobody platforms for antiviral constructs: mucosal immunotherapy prospects","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.prrv.2026.09.005_b0325","unstructured":"Mei Y, Chen Y, Sivaccumar JP et al. Research progress and applications of nanobody in human"},{"key":"10.1016\/j.prrv.2026.09.005_b0330","unstructured":"Lai S. et al. Clinical and preclinical development supporting IN-002 as the first inhaled monoclonal antibody treatment for RSV. Presented at 9th RSVVW Conference, in Rome, February 2026."},{"issue":"2","key":"10.1016\/j.prrv.2026.09.005_b0335","first-page":"346","article-title":"Live-attenuated intranasal RSV vaccine RSV\/6120\/\u0394NS2\/1030s in young children","volume":"229","author":"Shefchek","year":"2023","journal-title":"J Infect Dis."},{"issue":"9","key":"10.1016\/j.prrv.2026.09.005_b0340","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500026","article-title":"Live-attenuated intranasal RSV vaccine in infants and toddlers","volume":"4","author":"Idoko","year":"2025","journal-title":"NEJM Evid."},{"key":"10.1016\/j.prrv.2026.09.005_b0345","unstructured":"Della Cioppa G. et al. Safety, immunogenicity, and dose ranging of a bivalent RSV and hMPV glycoprotein F-molecular clamp vaccinee cadidate in older adults \u2013 Presented at 9th RSVVW Conference, in Rome, February 2026."},{"issue":"6","key":"10.1016\/j.prrv.2026.09.005_b0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/vaccines13060569","article-title":"Vaccine development for human pneumoviruses","volume":"13","author":"Mboup","year":"2025","journal-title":"Vaccines (Basel)."},{"issue":"4","key":"10.1016\/j.prrv.2026.09.005_b0355","article-title":"RSV and hMPV combination VLP vaccine in adults 60\u201375 years: phase 1 trial. Open Forum","volume":"12","author":"Shapiro","year":"2025","journal-title":"Infect Dis."},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0360","doi-asserted-by":"crossref","first-page":"e2576","DOI":"10.1002\/rmv.2576","article-title":"Systematic review of the efficacy and safety of RSV-specific monoclonal antibodies and antivirals in development","volume":"34","author":"Sevendal","year":"2024","journal-title":"Rev Med Virol."},{"issue":"12","key":"10.1016\/j.prrv.2026.09.005_b0365","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2313551","article-title":"AIRFLO Study Group. Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection","volume":"391","author":"Zhao","year":"2024","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.prrv.2026.09.005_b0370","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1021\/acs.jmedchem.0c01882","article-title":"Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion","volume":"64","author":"Cockerill","year":"2021","journal-title":"J Med Chem."},{"issue":"22","key":"10.1016\/j.prrv.2026.09.005_b0375","first-page":"193","article-title":"WHO position paper on immunization to protect infants against respiratory syncytial virus disease, May 2025","volume":"100","author":"World Health Organization","year":"2025","journal-title":"Wkly Epidemiol Rec."},{"key":"10.1016\/j.prrv.2026.09.005_b0380","unstructured":"Dookhun D, Ernst E, Del Lero N, et al. Mixed strategy of monoclonal antibody and maternal immunisation on RSV hospitalisations in Luxembourg, 2022\u20132025. Presented at: ESPID; 26\u201330 May 2025."},{"key":"10.1016\/j.prrv.2026.09.005_b0385","unstructured":"Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement.Pediatrics. 2025 Nov 1;156(5):e2025073923."},{"issue":"5","key":"10.1016\/j.prrv.2026.09.005_b0390","article-title":"Recommendations for the prevention of RSV disease in infants and children: policy statement","volume":"156","author":"American Academy of Pediatrics Committee on Infectious Diseases","year":"2025","journal-title":"Pediatrics"},{"key":"10.1016\/j.prrv.2026.09.005_b0395","unstructured":"Societ\u00e0 Italiana di Pediatria; Societ\u00e0 Italiana di Neonatologia. Virus respiratorio sinciziale (VRS): raccomandazioni unificate per la profilassi con nirsevimab \u2013 stagione 2025\u20132026 [Internet]. Roma: SIP; 2025 Sep 19 [cited 2026 Feb 12]. Available from:https:\/\/sip.it\/2025\/09\/19\/virus-respiratorio-sinciziale-vrs-raccomandazioni-unificate-sip-e-sin-per-la-profilassi-con-nirsevimab."},{"key":"10.1016\/j.prrv.2026.09.005_b0400","unstructured":"American Academy of Pediatrics. RSV immunization administration-nirsevimab and clesrovimab (updated guidance). AAP; 2025."}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:41:52Z","timestamp":1792096912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S1526054226000795"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.09.005","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RSV in children: an evolving story from high burden to universal prevention","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}